Royal Bank of Canada’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
|
|||||
|
2025
Q1 | $1K | Sell |
|
|||||
|
2024
Q4 | $4K | Buy |
|
|||||
|
2024
Q3 | $1K | Sell |
|
|||||
|
2024
Q2 | $272K | Buy |
|
|||||
|
2024
Q1 | $173K | Sell |
|
|||||
|
2023
Q4 | $153K | Buy |
|
|||||
|
2023
Q3 | $56K | Sell |
|
|||||
|
2023
Q2 | $411K | Buy |
|
|||||
|
2023
Q1 | $221K | Sell |
|
|||||
|
2022
Q4 | $297K | Buy |
|
|||||
|
2022
Q3 | $203K | Buy |
|
|||||
|
2022
Q2 | $94K | Buy |
|
|||||
|
2022
Q1 | $102K | Sell |
|
|||||
|
2021
Q4 | $536K | Sell |
|
|||||
|
2021
Q3 | $1.42M | Buy |
|
|||||
|
2021
Q2 | $1.24M | Buy |
|
|||||
|
2021
Q1 | $693K | Buy |
|
|||||
|
2020
Q4 | $607K | Sell |
|
|||||
|
2020
Q3 | $529K | Sell |
|
|||||
|
2020
Q2 | $621K | Sell |
|
|||||
|
2020
Q1 | $510K | Sell |
|
|||||
|
2019
Q4 | $745K | Buy |
|
|||||
|
2019
Q3 | $583K | Buy |
|
|||||
|
2019
Q2 | $539K | Buy |
|
|||||
|
2019
Q1 | $174K | Sell |
|
|||||
|
2018
Q4 | $197K | Sell |
|
|||||
|
2018
Q3 | $716K | Buy |
|
|||||
|
2018
Q2 | $613K | Buy |
|
|||||
|
2018
Q1 | $623K | Buy |
|
|||||
|
2017
Q4 | $280K | Sell |
|
|||||
|
2017
Q3 | $360K | Sell |
|
|||||
|
2017
Q2 | $540K | Sell |
|
|||||
|
2017
Q1 | $606K | Buy |
|
|||||
|
2016
Q4 | $305K | Buy |
|
|||||
|
2016
Q3 | $353K | Buy |
|
|||||
|
2016
Q2 | $247K | Buy |
|
|||||
|
2016
Q1 | $163K | Buy |
|
|||||
|
2015
Q4 | $7K | Buy |
|